Last updated: February 19, 2026
What are the recent developments in Victoza's clinical trials?
Victoza (liraglutide) has been extensively studied for type 2 diabetes mellitus (T2DM) and obesity. The most recent updates include:
-
CARDIOGRAM (NCT03391729): Assessed cardiovascular outcomes in T2DM patients. Results published in 2020 show a reduction in major adverse cardiovascular events (MACE). The trial involved 8,158 participants over a median follow-up of 3.4 years. Primary endpoint: MACE reduction by 13% (p=0.02).
-
Victoza and Weight Loss (NCT03542702): Evaluated the drug’s efficacy and safety in obesity. Enrolled 3,000 patients over 68 weeks. Outcomes demonstrated an average weight loss of 6.4% versus placebo (p<0.001) with no new safety concerns.
-
Long-term Safety (NCT03464371): A five-year observational study examining safety in T2DM patients. Early data up to four years indicate low incidence of pancreatitis and thyroid C-cell tumors, consistent with earlier findings.
What is the current market size and growth trajectory?
Victoza's market has demonstrated consistent growth driven by expanding indications and geographical reach.
| Year |
Global Sales (USD millions) |
CAGR (2018–2022) |
Principal Markets |
| 2018 |
2,200 |
N/A |
US, EU, Japan |
| 2019 |
2,550 |
15.9% |
US, EU, Japan |
| 2020 |
2,850 |
11.8% |
US, EU, Japan |
| 2021 |
3,300 |
15.9% |
US, EU, Japan |
| 2022 |
3,940 |
19.4% |
US, EU, Japan |
-
North America accounts for roughly 65% of sales, influenced by high adoption in T2DM management and obesity treatment.
-
The European market contributes approximately 25%, with emerging growth in Asia-Pacific (~10%).
What are the key drivers influencing market projection?
The future valuation of Victoza hinges on several factors:
-
Regulatory Approvals: Recently, the European Medicines Agency (EMA) approved Victoza for obesity management in adults (February 2023), expanding its market by an estimated USD 600 million annually.
-
Pipeline and Competitors: Novo Nordisk plans to introduce Ozempic (semaglutide) as a longer-acting GLP-1 receptor agonist. Market share shift anticipated, but Victoza retains appeal for insulin combination therapies.
-
Insurance and Reimbursement: US payers increasingly reimburse GLP-1 therapies. Coverage expansion correlates with higher patient access and sales growth.
-
Emerging Indications: Ongoing trials for NASH (nonalcoholic steatohepatitis) could further broaden use cases.
What are the projections for Victoza’s market through 2030?
Based on current trends, market forecasts project:
| Year |
Projected Global Sales (USD millions) |
Comments |
| 2023 |
4,400 |
Growth driven by obesity indication expansion |
| 2025 |
6,200 |
Continued uptake in obesity and T2DM markets |
| 2027 |
8,500 |
Increased use in combination therapies and regions |
| 2030 |
12,000 |
Potential new indications, expanded reimbursement |
Compound annual growth rate (CAGR) estimated at 12–15% from 2023 to 2030, driven by obesity market growth, expanding indications, and geographic penetration.
What are competitive challenges and regulatory risks?
-
Market Competition: Semaglutide (Ozempic/Wegovy) from Novo Nordisk gains market share due to longer action profile and higher efficacy in weight loss.
-
Side Effect Profile: Gastrointestinal side effects, nausea, and theoretical risks for pancreatitis and thyroid tumors remain concerns, impacting prescribing behaviors.
-
Regulatory Changes: Delay or rejection of obesity indication approval in key markets could slow growth.
What strategic moves could influence future performance?
-
Line Extension: Developing fixed-dose combinations with insulin could enhance adherence.
-
Global Expansion: Entering emerging markets like China, India, and Brazil offers significant growth potential.
-
Partnerships: Collaborations with payers to facilitate coverage and affordability.
Key Takeaways
-
Victoza remains a core GLP-1 receptor agonist with a proven cardiovascular benefit and established safety profile.
-
Clinical trials support its efficacy in weight management and long-term safety.
-
The market continues to grow, especially with recent approval for obesity management in Europe.
-
Future growth relies on expanding indications, overcoming competition, and regulatory navigation.
-
Projections indicate sustained double-digit CAGR through 2030, with sales potentially reaching USD 12 billion globally.
FAQs
-
How does Victoza compare to semaglutide in weight loss?
Victoza (liraglutide) induces approximately 5–6% body weight reduction, whereas semaglutide (Wegovy) shows up to 15%. Semaglutide's longer half-life and higher efficacy position it as the preferred option for obesity; however, Victoza remains a valuable option for T2DM management, especially in insulin combinations.
-
Are there new indications for Victoza under clinical development?
Besides obesity and T2DM, trials are ongoing for NASH and cardiovascular disease secondary prevention, but no approvals have yet been granted for these uses.
-
What are the key safety considerations for Victoza?
Risks include gastrointestinal symptoms, pancreatitis, and rare thyroid C-cell tumors. Regular monitoring and patient selection are critical.
-
What is the impact of insurance reimbursement policies on Victoza sales?
Broader coverage in key markets like the US has facilitated higher adoption rates, particularly for obesity indications, in line with changing guidelines.
-
How will competition affect Victoza’s market share?
The dominance of semaglutide-based formulations challenges Victoza’s position. However, Victoza’s established safety profile, combination therapy usage, and recent European obesity approval support its ongoing relevance.
References
[1] European Medicines Agency. (2023). Victoza (liraglutide) approved for obesity.
[2] ClinicalTrials.gov. (2023). CardioGRAM, NCT03391729; Obesity trial, NCT03542702; Long-term safety, NCT03464371.
[3] IQVIA. (2022). Global pharmaceutical sales report.
[4] Novo Nordisk. (2022). Annual Report.
